XML 85 R74.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2024 | Mar. 31, 2023
Segment Reporting Information [Line Items] |  |
Sales | $ 15,775 | $ 14,487
Increase in hedge revenue | 54 | 99
Revenue related to the sale of the marketing rights | 61 | 51
U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,478 | 6,659
Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,297 | 7,828
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 15,517 | 14,212
Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,410 | 6,599
Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 8,107 | 7,614
Corporate, Non-Segment |  |
Segment Reporting Information [Line Items] |  |
Sales | 258 | 275
Corporate, Non-Segment | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 68 | 60
Corporate, Non-Segment | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 190 | 214
Pharmaceutical | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 14,006 | 12,721
Pharmaceutical | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,936 | 6,117
Pharmaceutical | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,070 | 6,604
Pharmaceutical | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,947 | 5,795
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,119 | 3,485
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,828 | 2,310
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 292 | 275
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 135 | 142
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 157 | 133
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 255 | 232
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 173 | 153
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 82 | 79
Pharmaceutical | Operating Segments | Welireg |  |
Segment Reporting Information [Line Items] |  |
Sales | 85 | 42
Pharmaceutical | Operating Segments | Welireg | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 77 | 41
Pharmaceutical | Operating Segments | Welireg | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7 | 1
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 43
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 30
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 12 | 12
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,249 | 1,972
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 488 | 416
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,761 | 1,556
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 570 | 528
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 438 | 421
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 133 | 107
Pharmaceutical | Operating Segments | Vaxneuvance |  |
Segment Reporting Information [Line Items] |  |
Sales | 219 | 106
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 161 | 94
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 13
Pharmaceutical | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 216 | 297
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 149 | 180
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 67 | 117
Pharmaceutical | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 96
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6 | 40
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 56
Pharmaceutical | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 440 | 487
Pharmaceutical | Operating Segments | Bridion | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 329 | 276
Pharmaceutical | Operating Segments | Bridion | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 111 | 210
Pharmaceutical | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 174 | 129
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 74 | 54
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 100 | 75
Pharmaceutical | Operating Segments | Dificid |  |
Segment Reporting Information [Line Items] |  |
Sales | 73 | 65
Pharmaceutical | Operating Segments | Dificid | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 68 | 62
Pharmaceutical | Operating Segments | Dificid | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 5 | 3
Pharmaceutical | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 50
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 33 | 27
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 23 | 23
Pharmaceutical | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 60
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 8 | 14
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 48 | 46
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |
Segment Reporting Information [Line Items] |  |
Sales | 98 | 99
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 83
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 8 | 16
Pharmaceutical | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 70 | 59
Pharmaceutical | Operating Segments | Adempas | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 70 | 59
Pharmaceutical | Operating Segments | Lagevrio |  |
Segment Reporting Information [Line Items] |  |
Sales | 350 | 392
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 45 | (2)
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 305 | 394
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 111 | 123
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 52
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 71
Pharmaceutical | Operating Segments | Delstrigo |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 44
Pharmaceutical | Operating Segments | Delstrigo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 12 | 11
Pharmaceutical | Operating Segments | Delstrigo | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 44 | 33
Pharmaceutical | Operating Segments | Pifeltro |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 34
Pharmaceutical | Operating Segments | Pifeltro | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 29 | 24
Pharmaceutical | Operating Segments | Pifeltro | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 13 | 10
Pharmaceutical | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 46 | 56
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 15 | 16
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 32 | 40
Pharmaceutical | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 184 | 180
Pharmaceutical | Operating Segments | Simponi | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 184 | 180
Pharmaceutical | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 51
Pharmaceutical | Operating Segments | Remicade | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 51
Pharmaceutical | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 419 | 551
Pharmaceutical | Operating Segments | Januvia | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 183 | 271
Pharmaceutical | Operating Segments | Januvia | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 236 | 280
Pharmaceutical | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 251 | 329
Pharmaceutical | Operating Segments | Janumet | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 56
Pharmaceutical | Operating Segments | Janumet | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 212 | 272
Pharmaceutical | Operating Segments | Other pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 576 | 626
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 157 | 171
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 419 | 457
Animal Health | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,511 | 1,491
Animal Health | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 474 | 482
Animal Health | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,037 | 1,010
Animal Health | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 850 | 849
Animal Health | Operating Segments | Livestock | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 166 | 174
Animal Health | Operating Segments | Livestock | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 683 | 676
Animal Health | Operating Segments | Companion Animal |  |
Segment Reporting Information [Line Items] |  |
Sales | 661 | 642
Animal Health | Operating Segments | Companion Animal | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 308 | 308
Animal Health | Operating Segments | Companion Animal | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 354 | $ 334

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DelstrigoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PifeltroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |